Product Description
OTX008 is a calixarene derivative designed to bind the Gal1 amphipathic _-sheet conformation. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25042151/)
Mechanisms of Action: GAL1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company Founding Year: 1668
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01724320 |
OTX008_101 | P1 |
Unknown status |
Oncology Solid Tumor Unspecified |
2013-05-01 |
2023-12-08 |
Primary Endpoints|Treatments |